Avsnitt
-
People living with HIV who’ve had criminal legal involvement face significant challenges that complicate their ability to remain in the HIV care continuum. Many, while incarcerated, have stopped treatment, and once back in the community have been reluctant to resume ART. Why? What are the key drivers behind their disengagement from care? What can clinicians do to encourage these patients to return to treatment? What strategies have been tried, and what’s been shown to work? What does the evidence say?
Post-test for CME credits: https://elit.dkbmed.com/issues/213/test
Hosted on Acast. See acast.com/privacy for more information.
-
In this issue: Fatigue. It’s one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient’s life. What can clinicians do to better identify MS fatigue? And what do they need to know to better provide management effectively tailored to each patient?
Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/211/test)
Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/210)
Hosted on Acast. See acast.com/privacy for more information.
-
Saknas det avsnitt?
-
In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the current evidence show about when to prescribe high-efficacy disease modifying therapies? What activity limitations should be placed on patients with POMS?
Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/209/test)
Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/208)
Hosted on Acast. See acast.com/privacy for more information.
-
Widespread use of highly effective ART has increased the life expectancy of people living with HIV (PLWH) to close to that of the general population. But despite highly effective viral suppression, the risks for cardiovascular diseases continue to increase in these individuals. So too do the risks of neurocognitive impairment.
Post-test for CME credits: https://elit.dkbmed.com/issues/206/test
Hosted on Acast. See acast.com/privacy for more information.
-
Current ART regimens can successfully manage HIV infection in nearly all PLWH. But what happens when a patient with HIV is coinfected with a dangerous pathogen ART alone cannot handle? Two of the most common are hepatitis B and latent tuberculosis infection.
Post-test for CME credits: https://elit.dkbmed.com/issues/203/test
Hosted on Acast. See acast.com/privacy for more information.
-
Pregnancy and menopause — for many women, these are two of the most significant healthcare events in their lives. For WLWH (women living with HIV) and their healthcare providers, managing these life-changing periods is often complicated by many questions.
Post-test for CME credits: https://elit.dkbmed.com/issues/201
Hosted on Acast. See acast.com/privacy for more information.
-
Mild asthma. For patients showing wheezing and shortness of breath on moderate exertion, it’s one of the most common diagnoses, even when breath sounds are clear and pulmonary function testing is normal.
What makes mild asthma “mild”? The key guidelines base the stage of a patient’s asthma on how difficult it is to treat. Does that mean the frequency of symptom occurrence? How often a rescue inhaler needs to be used? The frequency and severity of pulmonary exacerbations?
How should mild asthma be treated? What are the risks and benefits of short-acting beta agonists versus long-acting beta agonists versus inhaled corticosteroids? Which combinations might be appropriate for which patients?
Join us in this issue of ePulmonology Review, as Dr. Fawzy from the Johns Hopkins University School of Medicine’s Division of Pulmonary and Critical Care discusses these and other issues important to providing the best care for patients with mild asthma.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/197/test
Hosted on Acast. See acast.com/privacy for more information.
-
Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it all mean to practitioners in the clinic?
Post test for CME/CE credit: https://elit.dkbmed.com/issues/195/test
Hosted on Acast. See acast.com/privacy for more information.
-
In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marginalized individuals at risk for or living with HIV. In this Part 2 issue, he again calls upon two front-line clinicians in the fight to end the HIV epidemic in the U.S. — Nicky Mehtani, MD, from UCSF Medical Center in San Francisco, and Vanessa Loukas, NP, from Boston University’s Chobanian & Avedisian School of Medicine —to share their clinical approaches.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/191/test
Hosted on Acast. See acast.com/privacy for more information.
-
Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved populations? How can they provide meaningful, helpful, and culturally sensitive care? What barriers continue to prevent their being brought into the HIV care continuum?
Hosted on Acast. See acast.com/privacy for more information.
-
Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved populations? How can they provide meaningful, helpful, and culturally sensitive care? What barriers continue to prevent their being brought into the HIV care continuum?
Hosted on Acast. See acast.com/privacy for more information.
-
A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?
Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/183/test
Companion newsletter: https://elit.dkbmed.com/issues/182
Hosted on Acast. See acast.com/privacy for more information.
-
NfL — neurofilament light, from the blood, not the CSF. Is it a reliable indicator of MS activity, a predictor of relapse-related disability, and a monitor of treatment efficacy? OCT — optical coherence tomography. Fast, safe, reliable, and repeatable, it can reveal the cellular layers inside the retina. But how well does what OCT shows correlate with outcomes of importance in MS? And most important, how can these new biomarkers help clinicians care for their patients with MS now?
Join us, as guest author Dr. Emily Schorr from the Department of Neurosciences at the University of California San Diego, addresses some of these questions in this issue of eMultipleSclerosis Review.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/181/test
Companion newsletter: https://elit.dkbmed.com/issues/180
Hosted on Acast. See acast.com/privacy for more information.
-
A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?
Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.
Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/179/test)
Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/175)
Hosted on Acast. See acast.com/privacy for more information.
-
Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?
Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.
Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)
Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)
Hosted on Acast. See acast.com/privacy for more information.
-
What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?
Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
-
Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?
Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
-
Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services?
These are some of the questions Guest Author Dr. Kathleen McManus, from the Division of Infectious Diseases and International Health at the University of Virginia, discusses in this issue of eHIV Review.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
-
Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?
Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
- Visa fler
